103. Phase I/IIa, Open-Labeled, Dose Escalation Clinical Study Using DVC1-0101 (F-Gene-Deleted Non-Transmissible Recombinant Sendai Virus Vector Expressing Human FGF-2) to Treat Peripheral Arterial Disease
Molecular Therapy - United States
doi 10.1016/s1525-0016(16)36675-8
